Petrovax: Reflamade (phosphomycin) Drug for the treatment of urinary tract infections

2024: Performance of "Reflamade"

the Russian urologists An antibacterial drug of the company "" Petrovax for the treatment of urinary tract infections (UTI) has appeared in the arsenal. Reflux (phosphomycin) helps to cope with acute and recurrent forms of cystitis. A single dose provides clinical and microbiological efficacy comparable to longer-lasting antibacterial therapy. Phosphomycin has a low level of E. coli resistance among antibiotics those used Russia in the treatment of UTIs. The company announced this on November 5, 2024.

Urinary tract infections (UTIs) rank third among the most common infectious diseases and first in the prescription of antibacterial drugs. Cystitis is one of the most common infectious-inflammatory diseases of the urinary tract. In Russia alone, 26-36 million cases of cystitis are registered.

Pains, burning, cuts, frequent urge to urinate - these symptoms of cystitis are familiar to many women. During life, acute cystitis is carried by 20-25% of women, every third of them has a recurrence of the disease within a year, and in 10% it goes into a chronic recurrent form. Antibacterial therapy is most often used to treat the disease, since the main causative agent of the infection is the uropathogenic Escherichia coli (E. coli), which is detected in 75% of patients, - explained Leonid Grigorievich Spivak, MD, professor at the Institute of Urology and Human Reproductive Health of the First Moscow State Medical University named after IM Sechenov.

Antimicrobial resistance undermines modern medicine and endangers the lives of millions of people, "said WHO Director-General Dr Tedros Adhanom Ghebreyesus.

Data from the international NoDARS study support a high level of E. coli resistance to a wide range of antibiotics. At the same time, E. coli is highly sensitive to phosphomycin, this is one of the few drugs to which the total level of E. coli resistance in Russia was 1.3%.

A single dose is comparable to the clinical, microbiological, and safety profiles of women with acute uncomplicated cystitis.

Antibacterial therapy with Reflameid (phosphomycin) is indicated for acute bacterial cystitis, bacterial nonspecific urethritis, postoperative UTIs, as well as for the prevention of infections in urinary tract surgery and transurethral diagnostic studies.